Fig. 3

Changes in stimulated CGRP and SP release (-fold of basal release) in experiments with pre-treatment of fremanezumab vs. isotype control antibody (A, B) and in experiments with galcanezumab vs. vehicle (C, D). Stimulation in A and C was performed with 500 nM capsaicin, in C and D with 100 nM capsaicin. One-way ANOVA, *** p < 0.0005, ** p < 0.005, * p < 0.05. Numbers in bars represent numbers of experiments. Data are from Dux et al. 2022 and Friedrich et al. 2024